A trial to investigate the combination of hyaluronidase (PEGPH20) and a PD-1 inhibitor in patients with high-hyaluronan non-small cell lung cancer

Trial Profile

A trial to investigate the combination of hyaluronidase (PEGPH20) and a PD-1 inhibitor in patients with high-hyaluronan non-small cell lung cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2015

At a glance

  • Drugs Hyaluronidase (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2015 New trial record
    • 07 Jan 2015 According to a Halozyme Therapeutics media release, this trial is expected to begin in the second half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top